Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GALT Galectin Therapeutics	$1.31 +2.3%	$1.37	$0.73 ▼ $3.17	$82.91M	0.62	318,074 shs	185,644 shs
JSPR Jasper Therapeutics	$4.77	$4.53	$3.13 ▼ $26.84	$71.66M	2.74	292,578 shs	132,289 shs
LSTA Lisata Therapeutics	$2.67 -1.1%	$2.29	$1.87 ▼ $4.20	$23.01M	0.95	21,502 shs	7,742 shs
MCRB Seres Therapeutics	$7.23 -5.7%	$10.00	$6.53 ▼ $30.60	$63.13M	2.89	146,614 shs	61,808 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GALT Galectin Therapeutics	+2.34%	+1.55%	-0.76%	-13.82%	-57.05%
JSPR Jasper Therapeutics	0.00%	-5.36%	+0.85%	-17.76%	-80.06%
LSTA Lisata Therapeutics	+1.14%	+4.71%	+5.53%	+11.72%	-9.80%
MCRB Seres Therapeutics	-5.74%	-12.26%	-28.27%	-51.81%	-60.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GALT Galectin Therapeutics	1.1317 of 5 stars	3.0	0.0	0.0	3.3	1.7	0.0
JSPR Jasper Therapeutics	2.4886 of 5 stars	3.5	2.0	0.0	3.6	1.7	0.6
LSTA Lisata Therapeutics	2.9597 of 5 stars	3.5	5.0	0.0	2.7	0.0	1.3
MCRB Seres Therapeutics	3.2111 of 5 stars	2.9	3.0	4.6	1.6	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GALT Galectin Therapeutics	2.00	Hold	$11.00	739.69% Upside
JSPR Jasper Therapeutics	3.00	Buy	$62.22	1,204.45% Upside
LSTA Lisata Therapeutics	3.00	Buy	$15.00	461.80% Upside
MCRB Seres Therapeutics	1.80	Reduce	$73.67	918.90% Upside

Current Analyst Ratings Breakdown

Latest LSTA, GALT, JSPR, and MCRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00
5/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
4/2/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/20/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/14/2025	MCRB Seres Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $15.00
3/11/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.01) per share	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A
LSTA Lisata Therapeutics	$1M	23.00	N/A	N/A	$5.88 per share	0.45
MCRB Seres Therapeutics	$126.33M	0.50	N/A	N/A	($0.35) per share	-20.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GALT Galectin Therapeutics	-$41.07M	-$0.72	N/A	N/A	N/A	N/A	N/A	-163.15%	8/11/2025 (Estimated)
JSPR Jasper Therapeutics	-$64.46M	-$5.24	N/A	N/A	N/A	N/A	-67.64%	-58.53%	8/12/2025 (Estimated)
LSTA Lisata Therapeutics	-$20.84M	-$2.30	N/A	N/A	N/A	N/A	-51.19%	-45.16%	8/11/2025 (Estimated)
MCRB Seres Therapeutics	-$113.72M	-$4.60	N/A	N/A	N/A	N/A	N/A	-55.08%	8/12/2025 (Estimated)

Latest LSTA, GALT, JSPR, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	LSTA Lisata Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
3/31/2025	Q4 2024	GALT Galectin Therapeutics	-$0.16	-$0.19	-$0.03	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GALT Galectin Therapeutics	N/A	1.13	1.13
JSPR Jasper Therapeutics	N/A	7.61	7.61
LSTA Lisata Therapeutics	N/A	8.03	8.03
MCRB Seres Therapeutics	N/A	1.12	1.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GALT Galectin Therapeutics	11.68%
JSPR Jasper Therapeutics	79.85%
LSTA Lisata Therapeutics	8.94%
MCRB Seres Therapeutics	59.34%

Insider Ownership

Company	Insider Ownership
GALT Galectin Therapeutics	50.10%
JSPR Jasper Therapeutics	2.70%
LSTA Lisata Therapeutics	9.60%
MCRB Seres Therapeutics	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GALT Galectin Therapeutics	9	63.29 million	31.32 million	Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.60 million	Optionable
LSTA Lisata Therapeutics	30	8.62 million	7.63 million	Not Optionable
MCRB Seres Therapeutics	330	8.73 million	162.03 million	Optionable

LSTA, GALT, JSPR, and MCRB Headlines

Recent News About These Companies

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 27 at 7:00 AM | globenewswire.com

Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?

May 23, 2025 | zacks.com

Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average - Here's Why

May 19, 2025 | marketbeat.com

Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade

May 16, 2025 | zacks.com

StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold

May 11, 2025 | marketbeat.com

Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com

May 11, 2025 | marketbeat.com

Seres Therapeutics' (MCRB) Neutral Rating Reaffirmed at Chardan Capital

May 10, 2025 | marketbeat.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript

May 9, 2025 | insidermonkey.com

Chardan Capital Downgrades Seres Therapeutics (MCRB)

May 9, 2025 | msn.com

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025 | seekingalpha.com

Seres Therapeutics reports Q1 EPS $3.75, consensus $1.97

May 7, 2025 | msn.com

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025 | globenewswire.com

Seres Therapeutics Q1 2025 Earnings Preview

May 6, 2025 | msn.com

Why Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%

May 6, 2025 | aaii.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Hold" by Brokerages

May 5, 2025 | marketbeat.com

Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50-Day Moving Average - Here's What Happened

May 4, 2025 | marketbeat.com

Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com

May 3, 2025 | marketbeat.com

Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday

May 2, 2025 | marketbeat.com

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

April 29, 2025 | globenewswire.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Decrease in Short Interest

April 28, 2025 | marketbeat.com

Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split

April 24, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA, GALT, JSPR, and MCRB Company Descriptions

Galectin Therapeutics NASDAQ:GALT

$1.31 +0.03 (+2.34%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.33 +0.02 (+1.83%)

As of 04:05 AM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Jasper Therapeutics NASDAQ:JSPR

$4.77 0.00 (0.00%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$4.80 +0.03 (+0.61%)

As of 05/27/2025 07:55 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Lisata Therapeutics NASDAQ:LSTA

$2.67 -0.03 (-1.11%)

Closing price 05/27/2025 03:58 PM Eastern

Extended Trading

$2.66 -0.02 (-0.56%)

As of 05/27/2025 07:57 PM Eastern

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Seres Therapeutics NASDAQ:MCRB

$7.23 -0.44 (-5.74%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$7.61 +0.38 (+5.26%)

As of 05/27/2025 07:23 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time